## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full methods, figures, tables, or supplementary data
- **Shared manuscript claim summary** The authors propose that Huangqin decoction (HQD) and its compound Glabridin prevent progression from ulcerative colitis (UC) to colitis-associated colorectal cancer (CAC) by modulating MMP1/MMP3 activity, with STAT3 as a shared transcription factor, based on bioinformatics, network pharmacology, molecular docking, molecular dynamics, and murine in vivo experiments.
- **Visible evidence base** Abstract text only; no figures, tables, methods details, or statistical outputs provided
- **Missing materials affecting confidence** Full methods, all figures and tables, statistical analyses, docking scores, MD simulation parameters, animal model details, dosing regimens, and raw data

## Reviewer
- **Overall assessment** The abstract presents a plausible multi-step workflow combining computational and experimental approaches to identify a candidate compound and mechanism for preventing UC-to-CAC progression. However, the evidence as summarized is insufficient to establish the central mechanistic claim. The abstract reports outcomes without quantitative data, effect sizes, or statistical significance, and the logical chain from bioinformatics to in vivo validation contains gaps that cannot be assessed from the supplied material. The work may be of interest to researchers in natural product pharmacology and colitis-associated cancer, but the current abstract does not provide enough detail to evaluate technical soundness or reproducibility.
- **Who would be interested in the results, and why** Researchers in inflammatory bowel disease and colorectal cancer chemoprevention, natural product pharmacology, and network pharmacology methodology would be interested. The identification of a specific compound from a traditional Chinese medicine formula with a proposed molecular target could inform future drug development and mechanistic studies in colitis-associated carcinogenesis.
- **Major strengths** The study integrates multiple complementary approaches, including bioinformatics, network pharmacology, molecular docking, molecular dynamics, and in vivo validation, which is a comprehensive strategy. The identification of MMP1 and MMP3 as shared targets between UC and CRC, and STAT3 as a common transcription factor, provides a focused mechanistic hypothesis. The use of both computational and experimental methods strengthens the potential translational relevance.
- **Major Concerns**
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Evidence sufficiency
  - **Claim pointer** The abstract claims that Glabridin "reduces inflammation, extracellular matrix degradation, and the occurrence of epithelial-mesenchymal transition to prevent UC transforming into CAC by inhibiting the phosphorylation of STAT3 and regulating the activity of MMP1/3."
  - **Evidence pointer** Results section, item 6; location not provided
  - **Concern** The in vivo claim is stated without any quantitative data, such as disease activity indices, histological scores, tumor counts, protein or mRNA expression levels, or statistical comparisons. No effect sizes, confidence intervals, or p-values are reported. The abstract does not specify the mouse models used, the dosing regimen, the route of administration, or the number of animals per group.
  - **Why it matters** Without quantitative evidence and experimental details, the central mechanistic conclusion cannot be evaluated for validity, reproducibility, or biological significance. The claim that Glabridin prevents UC-to-CAC progression requires demonstration of statistically significant differences between treated and untreated groups across multiple relevant endpoints.
  - **Resolution test** Provide quantitative data from the in vivo experiments, including group sizes, statistical tests, and effect sizes for inflammation scores, tumor burden, MMP1/MMP3 activity, and STAT3 phosphorylation levels. Include details of the animal models, dosing, and treatment duration.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Logical coherence
  - **Claim pointer** The abstract states that "molecular docking and MD verified that the dockings between Glabridin and STAT3/MMP1/MMP3 are stable and reliable."
  - **Evidence pointer** Results section, item 5; location not provided
  - **Concern** The abstract does not report any docking scores, binding energies, MD simulation parameters, or stability metrics such as RMSD or RMSF. The term "stable and reliable" is subjective without numerical thresholds or comparison to controls. Additionally, the functional relevance of binding to STAT3 versus MMP1/MMP3 is not clarified, particularly whether Glabridin acts directly on these proteins or through upstream regulatory pathways.
  - **Why it matters** Molecular docking and MD results are only meaningful when quantitative criteria are provided. Without these, the claim of stable binding cannot be independently assessed. Furthermore, the relationship between binding affinity and the proposed inhibitory mechanism on STAT3 phosphorylation and MMP activity is not established.
  - **Resolution test** Report docking scores, binding free energies, and MD stability metrics with defined acceptance criteria. Clarify whether Glabridin binding to STAT3 affects its phosphorylation status and whether MMP1/MMP3 activity changes are direct or downstream effects.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** No
  - **Axis** Methodological transparency
  - **Claim pointer** The abstract claims that "joint analysis of UC and CRC gene sets resulted in 14 hub genes" and that "network pharmacology results show HQD has 133 core targets."
  - **Evidence pointer** Results section, items 1 and 2; location not provided
  - **Concern** The abstract does not specify the bioinformatics datasets used, the criteria for selecting hub genes, the network pharmacology databases, or the thresholds for target identification. The overlap between hub genes and core targets yielding only MMP1 and MMP3 is stated without showing the intersection analysis or the statistical significance of this overlap.
  - **Why it matters** Reproducibility of computational findings depends on explicit parameters, database versions, and selection criteria. Without these, the identification of MMP1 and MMP3 as key targets cannot be verified, and the possibility of selection bias or arbitrary thresholds cannot be excluded.
  - **Resolution test** Provide detailed methods for bioinformatics and network pharmacology analyses, including dataset identifiers, software versions, parameters, and statistical thresholds. Show the full intersection analysis and any enrichment or permutation testing used to support the significance of the identified targets.
- **Minor Comments**
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Clarity
  - **Affected element** Title
  - **Evidence pointer** Title; location not provided
  - **Issue** The title states that Glabridin "prevents the development" of UC into CAC, but the abstract only reports effects in mouse models, not in humans. The title may overstate the clinical implication.
  - **Required correction** Consider revising the title to specify "in a murine model" or "in preclinical models" to accurately reflect the evidence level.
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Completeness
  - **Affected element** Results section, item 4
  - **Evidence pointer** Results section, item 4; location not provided
  - **Issue** The statement that "STAT3 is a shared TF of MMP1 and MMP3" is presented without evidence of how this was determined, such as ChIP-seq data, promoter analysis, or literature support.
  - **Required correction** Provide the basis for this claim, either through experimental validation or citation of established regulatory relationships, and specify the method used to identify STAT3 as a shared transcription factor.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Terminology
  - **Affected element** Results section, item 6
  - **Evidence pointer** Results section, item 6; location not provided
  - **Issue** The phrase "regulating the activity of MMP1/3" is ambiguous. It is unclear whether this refers to expression levels, enzymatic activity, or both, and whether the regulation is direct or indirect.
  - **Required correction** Specify the measured parameter, such as mRNA expression, protein levels, or enzymatic activity, and clarify the direction of regulation (inhibition or activation).
- **Technical failings that need to be addressed before the case is established** R1-M1 and R1-M2 are blocking because the central mechanistic claim and the binding validation lack quantitative evidence. R1-M3 is important for reproducibility but not necessarily blocking if the full methods are provided in the manuscript.
- **Assessment against Nature-style criteria**  
  Originality: The combination of network pharmacology with experimental validation for a specific compound from HQD is not entirely novel, as similar approaches are common in natural product research. The specific focus on MMP1/MMP3 and STAT3 may offer some novelty, but this is not clearly differentiated from existing literature.  
  Scientific importance: The prevention of UC-to-CAC progression is clinically relevant, and identifying a bioactive compound from a traditional formula could have translational value. However, the importance is not fully established without robust in vivo data and mechanistic depth.  
  Interdisciplinary readership: The work spans bioinformatics, pharmacology, and cancer biology, which could attract a broad readership. However, the abstract lacks sufficient detail for specialists in any single discipline to evaluate the rigor.  
  Technical soundness: Cannot be assessed from the abstract alone. The absence of quantitative data, statistical analyses, and methodological details precludes evaluation of technical quality.  
  Readability for nonspecialists: The abstract is generally readable, but terms such as "hub genes," "network pharmacology," and "molecular dynamics" are used without brief explanation, which may limit accessibility for a general scientific audience.
- **Recommendation posture** Currently not established from the provided evidence. The abstract presents a promising hypothesis and workflow, but the lack of quantitative data and methodological transparency prevents assessment of the central claims. If the full manuscript provides robust experimental data with statistical support, the work could become supportive, but this cannot be determined from the abstract alone.

## Risk / unsupported claims
- The claim that Glabridin prevents UC-to-CAC progression in vivo is unsupported without quantitative data and statistical analysis.
- The claim that molecular docking and MD results are "stable and reliable" is unsupported without numerical metrics.
- The identification of MMP1 and MMP3 as key targets is not verifiable without details of the bioinformatics and network pharmacology methods.
- The statement that STAT3 is a shared transcription factor of MMP1 and MMP3 is unsupported without evidence of the determination method.
- The clinical relevance implied by the title is not supported by the abstract, which only describes mouse experiments.